Bank Pictet & Cie Europe AG Sells 225 Shares of Natera, Inc. (NASDAQ:NTRA)

Bank Pictet & Cie Europe AG lessened its holdings in Natera, Inc. (NASDAQ:NTRA) by 11.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,754 shares of the medical research company’s stock after selling 225 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Natera were worth $278,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Chartwell Investment Partners LLC boosted its stake in shares of Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after purchasing an additional 11,362 shares during the last quarter. Cerity Partners LLC boosted its stake in shares of Natera by 27.0% in the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Natera in the 3rd quarter valued at about $385,000. Everence Capital Management Inc. acquired a new stake in shares of Natera in the 4th quarter valued at approximately $573,000. Finally, First Turn Management LLC acquired a new stake in shares of Natera in the 3rd quarter valued at approximately $19,760,000. Institutional investors own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, insider John Fesko sold 663 shares of the firm’s stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the transaction, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 946 shares of the firm’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08. Following the completion of the transaction, the chief financial officer now directly owns 109,474 shares of the company’s stock, valued at $18,827,338.52. This represents a 0.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 305,454 shares of company stock valued at $51,290,625. 7.60% of the stock is owned by corporate insiders.

Natera Price Performance

Shares of NTRA opened at $173.39 on Friday. The stock has a market capitalization of $22.89 billion, a P/E ratio of -98.52 and a beta of 1.66. Natera, Inc. has a twelve month low of $68.03 and a twelve month high of $183.00. The company has a 50 day moving average of $167.75 and a 200-day moving average of $143.14. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Piper Sandler increased their price target on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Barclays assumed coverage on shares of Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price target on the stock. The Goldman Sachs Group increased their price target on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. TD Cowen increased their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $165.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.